SCHEMBL1028535

SCHEMBL1028535

CCOC(=O)Cc1c(Cl)ccc2ccc(C)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.43
▸ HSD17B10 Q99714 3/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ TDP1 Q9NUW8 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 4/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ CCR1 P32246 1/20 0.39
▸ CCR5 P51681 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ HTT P42858 3/20 0.39
▸ PKM P14618 1/20 0.39
▸ TRPM8 Q7Z2W7 1/20 0.39
▸ BDKRB2 P30411 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1030065 0.84 CCR1 (0.42) KDM4EHSD17B10MAPK1USP2TSHR
SCHEMBL1027497 0.83 KDM4E (0.38) KDM4ERAB9AMAPTKMT2ACCR1
SCHEMBL1029533 0.82 MEN1 (0.40) KDM4EHSD17B10MAPK1USP2TSHR
SCHEMBL27708521 0.79 RAB9A (0.47) KDM4EL3MBTL1RAB9AMAPTKMT2A
SCHEMBL31750243 0.78 KDM4E (0.42) KDM4EHSD17B10MAPK1USP2TSHR
SCHEMBL1030068 0.77 KDM4E (0.38) KDM4EMAPTKMT2ATHRBHTT
SCHEMBL27708535 0.76 RAD52 (0.40) KDM4ERAB9AMAPTKMT2ACCR1
SCHEMBL31750399 0.76 KDM4E (0.44) KDM4EHSD17B10MAPK1USP2TSHR
SCHEMBL31750118 0.76 KDM4E (0.40) KDM4EHSD17B10MAPK1USP2TSHR
SCHEMBL1429298 0.75 AKR1B1 (0.55) KDM4EHSD17B10MAPK1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426440-B2 Indolymaleimide derivatives NOVARTIS AG (CH) 2013-04-23 — — US disclosed
EP-2246346-B1 Indolylmaleimide derivatives as protein kinase inhibitors NOVARTIS AG (CH) 2012-10-24 — — EP disclosed
EP-1904482-B1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2011-01-19 — — EP disclosed
EP-2246346-A1 Indolylmaleimide derivatives as protein kinase inhibitors Novartis AG (CH) 2010-11-03 — — EP disclosed
US-20100273774-A1 INDOLYMALEIMIDE DERIVATIVES WAGNER JUERGEN 2010-10-28 — — US disclosed
US-7781438-B2 Indolylmaleimide derivatives NOVARTIS AG (CH) 2010-08-24 — — US disclosed
US-20080318975-A1 Indolylmaleimide Derivatives NOVARTIS AG (CH) 2008-12-25 — — US disclosed
EP-1904482-A2 INDOLYLMALEIMIDE DERIVATIVES Novartis AG (CH) 2008-04-02 — — EP disclosed
WO-2007006533-A2 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2007-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273774-A1 INDOLYMALEIMIDE DERIVATIVES IDO1, INMT, IDO2 KDM4E 1638/4885HSD17B10 1029/4885MAPK1 2787/4885
US-20080318975-A1 Indolylmaleimide Derivatives IDH3A, INMT, IDH3B KDM4E 207/4885HSD17B10 443/4885MAPK1 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback